DZNep treatment can markedly suppress H3K27 methylation (rather than H3K9 methylation) in diverse tumor cells (such as MB-468 BC cells) by depleting PRC2 component levels in cells (EZH2, SUZ12, and EED) (Tan et al., 2007)) (Figure 3). Here, EZH2 is linked to breast cancer.